Department of Biotechnology, All India Institute of Medical Sciences, New Delhi, India.
PLoS One. 2012;7(8):e43430. doi: 10.1371/journal.pone.0043430. Epub 2012 Aug 17.
RTS,S is the most advanced malaria vaccine candidate, currently under phase-III clinical trials in Africa. This Plasmodium falciparum vaccine contains part of the central repeat region and the complete C-terminal T cell epitope region (Th2R and Th3R) of the circumsporozoite protein (CSP). Since naturally occurring polymorphisms at the vaccine candidate loci are critical determinants of the protective efficacy of the vaccines, it is imperative to investigate these polymorphisms in field isolates. In this study we have investigated the genetic diversity at the central repeat, C-terminal T cell epitope (Th2R and Th3R) and N-terminal T cell epitope regions of the CSP, in P. falciparum isolates from Madhya Pradesh state of India. These isolates were collected through a 5-year prospective study aimed to develop a well-characterized field-site for the future evaluation of malaria vaccine in India. Our results revealed that the central repeat (63 haplotypes, n = 161) and C-terminal Th2R/Th3R epitope (24 haplotypes, n = 179) regions were highly polymorphic, whereas N-terminal non-repeat region was less polymorphic (5 haplotypes, n = 161) in this population. We did not find any evidence of the role of positive natural selection in maintaining the genetic diversity at the Th2R/Th3R regions of CSP. Comparative analysis of the Th2R/Th3R sequences from this study to the global isolates (n = 1160) retrieved from the GenBank database revealed two important points. First, the majority of the sequences (61%, n = 179) from this study were identical to the Dd2/Indochina type, which is also the predominant Th2R/Th3R haplotype in Asia (59%, n = 974). Second, the Th2R/Th3R sequences in Asia, South America and Africa are geographically distinct with little allele sharing between continents. In conclusion, this study provides an insight on the existing polymorphisms in the CSP in a parasite population from India that could potentially influence the efficacy of RTS,S vaccine in this region.
RTS,S 是最先进的疟疾疫苗候选者,目前正在非洲进行 III 期临床试验。这种恶性疟原虫疫苗包含部分环子孢子蛋白(CSP)的中心重复区和完整的 C 端 T 细胞表位区(Th2R 和 Th3R)。由于候选疫苗基因座的自然发生多态性是疫苗保护效力的关键决定因素,因此必须在现场分离株中研究这些多态性。在这项研究中,我们研究了印度中央邦疟原虫分离株中 CSP 中心重复区、C 端 T 细胞表位(Th2R 和 Th3R)和 N 端 T 细胞表位区的遗传多样性。这些分离株是通过一项为期 5 年的前瞻性研究收集的,目的是为未来在印度评估疟疾疫苗建立一个特征良好的现场地点。我们的研究结果表明,中心重复区(63 个单倍型,n=161)和 C 端 Th2R/Th3R 表位区(24 个单倍型,n=179)高度多态性,而 N 端非重复区则较少多态性(5 个单倍型,n=161)。我们没有发现任何证据表明正选择在维持 CSP Th2R/Th3R 区的遗传多样性方面发挥作用。将本研究的 Th2R/Th3R 序列与从 GenBank 数据库中检索到的全球分离株(n=1160)进行比较分析,揭示了两个重要的方面。首先,本研究中大多数序列(61%,n=179)与 Dd2/Indochina 型相同,该型也是亚洲主要的 Th2R/Th3R 单倍型(59%,n=974)。其次,亚洲、南美洲和非洲的 Th2R/Th3R 序列在地理上是不同的,各大洲之间很少有等位基因共享。总之,这项研究提供了印度寄生虫群体中 CSP 现有多态性的见解,这可能会影响该地区 RTS,S 疫苗的效力。